Mouth rinse
Phase 1Small molecule
Mouth rinse is one of 20 small molecule programs targeting Gingivitis. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Gingivitis
#DrugCompanyPhaseTrials
1Flagyl
DDePuy Orthopaedics
Approved
Peridex
DDexcel Pharma Technologies Ltd.
Approved
Cetylpyridinium Chloride
SanofiApproved
Tea Tree Oil
FFederal University of São Paulo
Approved
Triclosan
CColgate Palmolive
Phase 3
Active Comparator
ModernaPhase 2
Negative Control
GSKPhase 3
Test
RRespirent Pharmaceuticals Co Ltd.
Phase 2
Sodium Laural Sulfate
GSKPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mouth rinse. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Pennsylvania